Intelligence Β· Patent portfolio
Theravance Biopharma Ireland Patents
Full USPTO pharma patent portfolio for Theravance Biopharma Ireland β grant dates, expiration, and drug cross-links.
- Patents
- 635
- Expiring β€24m
- 58
Quick answer
Theravance Biopharma Ireland has 635 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 58 expire within 24 months β use filters for patent-cliff planning.
-
US 7855221
Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
granted -
US 7851467
Carbamate compounds as 5-HT4 receptor agonists
granted -
US 7851631
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7851632
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7846973
Chemical process and new crystalline form
granted -
US 7842704
Compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor antagonist activity
granted -
US 7838535
Compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor antagonist activity
granted -
US 7834185
Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
granted -
US 7834041
Dual-acting antihypertensive agents
granted -
US 7829728
Diarymethyl and related compounds
granted -
US 7829583
Biphenyl derivatives
granted -
US 7816532
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7803812
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7790766
Pharmaceutical compositions of short-acting sedative hypnotic agent
granted -
US 7786136
Indazole-carboxamide compounds
granted -
US 7777077
Dual-acting antihypertensive agents
granted -
US 7772434
Crystalline form of a Ξ²2 adrenergic receptor agonist
granted -
US 7772239
Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 7772250
Compounds
granted -
US 7763637
Quinolinone-carboxamide compounds as 5-HT4, receptor agonists
granted -
US 7759363
Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists
granted -
US 7732441
Azabicycloalkane compounds
granted -
US 7728127
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7728004
Crystalline form of a quinolinone-carboxamide compound
granted -
US 7728104
Process for preparing glycopeptide phosphonate derivatives
granted -
US 7728006
Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 7728144
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7723470
Glycopeptide derivatives and pharmaceutical compositions containing the same
granted -
US 7713931
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7700550
Glycopeptide phosphonate derivatives
granted -
US 7700777
Crystalline forms of a biphenyl compound
granted -
US 7691878
Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
granted -
US 7687519
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7687521
Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
granted -
US 7683173
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7674908
Indazole-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 7671198
Process for preparing intermediates to 5-HT4 receptor agonist compounds
granted -
US 7662815
Diaryl ether Ξ²2 adrenergic receptor agonists
granted -
US 7659403
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7655621
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7649080
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7642355
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7638639
Substituted pyrrolidine and related compounds
granted -
US 7632847
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7629336
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7622587
Crystalline form of a benzimidazole-carboxamide medicinal compound
granted -
US 7622467
Aryl aniline derivatives as Ξ²2 adrenergic receptor agonists
granted -
US 7622508
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
granted
Frequently asked questions
How many patents does Theravance Biopharma Ireland have?
635 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Theravance Biopharma Ireland patents expire?
58 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory